JernbergTJohansonPHeldC, et al.Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA2011; 305: 1677–1684.
2.
GasiorMPresDWojakowskiW, et al.Causes of hospitalization and prognosis in patients with cardiovascular diseases. Secular trends in the years 2006–2014 according to the SILesian CARDiovascular database. Pol Arch Med Wewn2016; 126: 754–762.
3.
MozaffarianDBenjaminEJGoAS, et al.Heart disease and stroke statistics—2015 update: A report from the American Heart Association. Circulation2015; 131: e29–e322.
4.
KirchhofPBenussiSKotechaD, et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J2016; 37: 2893–2962.
5.
SchmittJDurayGGershBJ, et al.Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications. Eur Heart J2009; 30: 1038–1045.
6.
VioliFSolimanEZPignatelliP, et al.Atrial fibrillation and myocardial infarction: A systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc2016; 5: e003347–e003347.
7.
ForcadellMJVila-CórcolesAde DiegoC, et al.Incidence and mortality of myocardial infarction among Catalonian older adults with and without underlying risk conditions: The CAPAMIS study. Eur J Prev Cardiol2018; 25: 1822–1830.
8.
RuddoxVSandvenIMunkhaugenJ, et al.Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol2017; 24: 1555–1566.
9.
IbanezBJamesSAgewallS, et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J2018; 39: 119–177.
10.
Jortveit J, Pripp AH, Langørgen J, Halvorsen S. Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction. Eur J Prev Cardiol. 2019; 26: 1373–1382.
11.
GierlotkaMGasiorMWilczekK, et al.Temporal trends in the treatment and outcomes of patients With non-ST-segment elevation myocardial infarction in Poland from 2004–2010 (from the Polish Registry of Acute Coronary Syndromes). Am J Cardiol2012; 109: 779–786.
12.
SzummerKWallentinLLindhagenL, et al.Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: Experiences from the SWEDEHEART registry 1995–2014. Eur Heart J2017; 38: 3056–3065.
13.
StenestrandULindbackJWallentinL, et al.Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: A prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation2005; 112: 3225–3231.
14.
EikelboomJWConnollySJBoschJ, et al.Rivaroxaban with or without aspirin in stable cardiovascular disease. N J Med2017; 377: 1319–1330.
15.
DarmonABhattDLElbezY, et al.External applicability of the COMPASS trial: An analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J2018; 39: 750–757a.
16.
CannonCPBhattDLOldgrenJ, et al.Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med2017; 377: 1513–1524.
17.
ValgimigliMBuenoHByrneRA, et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg2018; 53: 34–78.
